Analysis by Japanese supercomputer Fugaku, which was recently named the world's fastest, has found some 30 existing medications that could be effective COVID-19 treatments, Kyoto University Prof. Yasushi Okuno announced on July 3, the Mainichi Shimbun reported.
According to the supercomputer's assessment, the candidate drug with the most potential was not known to be effective for coronavirus treatment. Okuno, a specialist in computational science for pharmaceutical development, says a Japanese firm holds the patent for this existing drug. He hopes to launch clinical research and a drug trial after negotiating with the manufacturer.
Okuno and a team of researchers ran simulations using Fugaku to see how 2,128 existing drugs, including anticancer agents and common cold medicine, bind to proteins unique to SARS-CoV-2 -- the novel coronavirus' scientific name -- and looked into how the drugs worked in the body on the molecular level. It appeared that the longer the agent stayed locked inside the keyhole-like spaces of the proteins, the stronger the binding and thus more likely the drug would be effective. The research team ranked the medications based on how long the agents were connected to the proteins.
The 12 drugs currently being tested overseas as potential COVID-19 treatment all ranked high in Fugaku's simulations, including antiparasitic drug Niclosamide, which came in second place. The medication that connected with the SARS-CoV-2 proteins the longest was Japanese, but Okuno says he can't name the drug due to potential patent infringement. Many other medications, whose efficacy as coronavirus treatments had been unknown, also ranked high in the simulations. The protein targeted in their research was the main protease of SARS-CoV-2. This enzyme works to replicate viruses in a human cell.
Comentarios